Clinical and Radiological Heterogeneity in Anti‐Neurofascin‐155 Autoimmune Nodopathy: A Case Series Analysis
Anti-NF155 nodopathy is a distinct, biomarker-trackable entity; corticosteroids and rituximab outperform IVIg, challenging conventional practice and highlighting the need for antibody testing, especially in young patients with severe demyelinating neuropathy.
Authors
- Noriko Isobe (ORCID: https://orcid.org/0000-0001-9525-4254)
- Keiichi Nakahara (ORCID: https://orcid.org/0000-0002-8931-8861)
- Michie Imamura
- Hidenori Ogata (ORCID: https://orcid.org/0000-0001-8932-9731)
- Mitsuharu Ueda (ORCID: https://orcid.org/0000-0002-6814-0582)
- Toshiya Nomura (ORCID: https://orcid.org/0000-0001-9657-5324)
- Yohei Misumi (ORCID: https://orcid.org/0000-0003-4372-2436)
- Hironori Mizutani (ORCID: https://orcid.org/0000-0002-2013-7368)
- T. Taguchi (ORCID: https://orcid.org/0009-0001-0931-4984)
- Masao Imura
Institutions
- Kyushu University (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Journal of the Peripheral Nervous System
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1111/jns.70077
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00